Sanofi stock pre-market at EUR 74.65: plus 2.44 percent
Published on 10/01/2026 at 08:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi stock was at EUR 74.65 pre-market at 8:47 a.m. CEST on October 1, 2026, up 2.44 percent versus the Lang & Schwarz prior close of EUR 72.87 on September 30, 2026.
Sanofi pre-market price
The Lang & Schwarz quote showed a bid of EUR 74.53 and an ask of EUR 74.76. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Sanofi stock.
Expanded antibody collaboration
Sanofi and Regeneron announced on October 1, 2026, that they had expanded their global antibody collaboration to include four next-generation, long-acting antibodies. The programs target interleukin-13, an interleukin-4xinterleukin-13 bispecific, interleukin-4 and interleukin-4 receptor alpha, according to Sanofi.
Regeneron will receive a USD 1 billion upfront payment from Sanofi and may receive up to an additional USD 7 billion in development, regulatory and commercial milestone payments. The companies will share development and commercialization costs and split future profits from the new programs equally worldwide. Sanofi will lead global commercial efforts, while Regeneron will lead research and development.
Programs and conference call
REGN20423 is in a Phase 1 clinical study for atopic dermatitis, while the other three antibodies are expected to enter clinical studies in 2027. Sanofi and Regeneron said they would host a conference call for investors and analysts at 2:00 p.m. CET on October 1, 2026.
